Stocktoria
GeoVax Labs, Inc. GOVX
GeoVax Labs, Inc. (GOVX) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.5M at a -862.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GOVX | GeoVax Labs, Inc. | 1/9 | — | — | — |
| ONTX | Traws Pharma, Inc. | 3/9 | — | 1.4 | — |
| RNAC | Cartesian Therapeutics, Inc. | 1/9 | -10.08 | — | -92.8% |
| UPB | Upstream Bio, Inc. | 2/9 | — | — | — |
| CYCN | Cyclerion Therapeutics, Inc. | 1/9 | — | — | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 1/9 | 14.17 | — | — |
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
FAQ
Is GOVX financially healthy?
GeoVax Labs, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does GOVX pay a dividend?
No, GeoVax Labs, Inc. does not currently pay a dividend.
How profitable is GOVX?
In FY2025, GeoVax Labs, Inc. had a net margin of -862.3% and a return on equity of -561.2%.
What is the analyst price target for GOVX?
The average Wall-Street price target for GeoVax Labs, Inc. is $10.00, about 1278.2% above the recent price, from 2 analysts.
Is GOVX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GeoVax Labs, Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.